DXVX Develops Groundbreaking Technology to Overcome mRNA Vaccine Storage Limitations
Verifies Possibility of Room-Temperature Storage for Over 10 Years Through Preliminary Research
Reporter: Kwon Kyu-Goo │ kwon9@yakup.com

DXVX has announced the development of a revolutionary vaccine technology aimed at addressing key limitations of existing mRNA vaccines, a breakthrough expected to significantly strengthen national health security. Partnering with Pohang University of Science and Technology (POSTECH), DXVX has been selected for the first ARPA-H project, which focuses on developing mRNA vaccines that can be stored long-term at room temperature.

The company explained that its project, part of the Korean ARPA-H national initiative, centers on creating mRNA vaccines with ultra-long-term stability at ambient temperatures. Preliminary research and simulations conducted in collaboration with POSTECH have already confirmed the possibility of preserving these vaccines for over 10 years at room temperature.

ARPA-H, a program designed to support the development of pioneering technologies that are not yet available globally, has recognized the potential of DXVX’s innovation. The company notes that their room-temperature, long-term vaccine storage technology is the first of its kind in the world.

DXVX CEO Kyu-Chan Kwon commented, “By overcoming challenges associated with mRNA vaccines—such as ultra-cold freezing, storage, distribution, and limited shelf life—we expect this technology to significantly expand global access to vaccines, ultimately enhancing human welfare. Commercializing long-term mRNA preservation technology will also help to strengthen national health security and establish a rapid response foundation for future pandemics.”